Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized ALN-RSV01 in Lung Transplant Patients with RSV Infection
2009-017487-16Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2009
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and Bronchiolitis Obliterans Syndrome (BOS) comparing ALN-RSV01 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Incidence of new or progressive bronchiolitis obliterans syndrome at Day 180. Started Dec 2009; status: completed.
02
Drugs
asvasiran
03
Conditions
respiratory syncytial virus disease (RSV)Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2009-017487-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017487-16.